Deadline: 18-10-2021
(Source: European Commission, DG Competition (COMP))
Scope of the procurement
Title: Ex Post Evaluation: EU Competition Enforcement and Acquisitions of Innovative Competitors in the Pharma Sector Leading to the Discontinuation of Overlapping Drug Research and Development Projects
Reference number: COMP/2021/OP/0002
Main CPV code
79311410 Economic impact assessment
Type of contract
Services
Short description:
Empirical research by Cunningham et al. (2021) suggests that in the pharmaceutical industry a considerable number of acquisitions might have as their object or effect the discontinuation of overlapping drug R&D projects to the detriment of innovation competition and ultimately consumers. Such acquisitions are commonly referred to as ‘killer acquisitions’. The study aims to determine what are the typical features of such killer acquisitions and obtain evidence on the prevalence of such acquisitions, as this would allow the Commission to determine which transactions in the pharmaceutical industry deserve closer scrutiny. A second objective of the study is to conduct ex post evaluations of selected past merger decisions. These case studies aim to assess whether in the concentrations notified to and examined by the Commission under the EU Merger Regulation, the Commission correctly anticipated the risks of possible discontinuations of competing lines of drug R&D projects.
Estimated total value
Value excluding VAT: 500 000.00 EUR
Information about lots
This contract is divided into lots: no
More information: https://etendering.ted.europa.eu/cft/cft-display.html?cftId=7774